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Background: Rescue or correction of CFTR function in native epithelia is the ultimate goal of CF therapeutics
development. Wild-type (WT) CFTR introduction and replacement is also of particular interest. Such therapies may
be complicated by possible CFTR self-assembly into an oligomer or multimer.
Results: Surprisingly, functional CFTR assays in native airway epithelia showed that the most common CFTR
mutant, ΔF508-CFTR (ΔF-CFTR), inhibits WT-CFTR when both forms are co-expressed. To examine more
mechanistically, both forms of CFTR were transfected transiently in varying amounts into IB3-1 CF human airway
epithelial cells and HEK-293 human embryonic kidney cells null for endogenous CFTR protein expression. Increasing
amounts of ΔF-CFTR inhibited WT-CFTR protein processing and function in CF human airway epithelial cells but not
in heterologous HEK-293 cells. Stably expressed ΔF-CFTR in clones of the non-CF human airway epithelial cell line,
CALU-3, also showed reduction in cAMP-stimulated anion secretion and in WT-CFTR processing. An ultimate test of
this dominant negative-like effect of ΔF-CFTR on WT-CFTR was the parallel study of two different CF mouse models:
the ΔF-CFTR mouse and the bitransgenic CFTR mouse corrected in the gut but null in the lung and airways. WT/ΔF
heterozygotes had an intermediate phenotype with regard to CFTR agonist responses in in vivo nasal potential
difference (NPD) recordings and in Ussing chamber recordings of short-circuit current (ISC) in vitro on primary
tracheal epithelial cells isolated from the same mice. In contrast, CFTR bitransgenic +/− heterozygotes had no
difference in their responses versus +/+ wild-type mice.
Conclusions: Taken altogether, these data suggest that ΔF-CFTR and WT-CFTR co-assemble into an oligomeric
macromolecular complex in native epithelia and share protein processing machinery and regulation at the level of
the endoplasmic reticulum (ER). As a consequence, ΔF-CFTR slows WT-CFTR protein processing and limits its
expression and function in the apical membrane of native airway epithelia. Implications of these data for the
relative health of CF heterozygous carriers, for CFTR protein processing in native airway epithelia, and for the
relative efficacy of different CF therapeutic approaches is significant and is discussed.
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CF is a monogenic disorder, a rare misfolded protein dis-
order, and the most common autosomal recessive gen-
etic disease found in the Caucasian population [1-3]. CF
is caused by mutations in CFTR that lead to reduced
surface expression and/or function of this cyclic AMP-
regulated chloride (Cl-) channel among other airway,
gastrointestinal and other epithelial tissue defects [1-4].
The most commonly occurring CF mutation is the
ΔF508-CFTR (ΔF-CFTR) mutation that occurs in ap-
proximately 70-90% of the CF population worldwide
[1-4]. This mutation causes a folding defect in the CFTR
protein that causes ER retention of the majority of the
ΔF-CFTR protein [1-6].
CF disease phenotype correlates better with CFTR geno-
type in the gastrointestinal (GI) tract, where secretion of
pancreatic enzymes and bile along with salt, bicarbonate,
and water is essential for function [4]. However, in the CF
lung and airways, there is little correlation between CFTR
genotype and lung and airways disease phenotype [4].
One ΔF-CFTR homozygous patient can have severe dis-
ease and another ΔF-CFTR homozygous patient can
present a more mild disease; this is the rationale for CF
siblings and twins genotype/phenotype correlation studies
currently in progress [7,8]. This lack of correlation may be
explained by: (a) secondary or modifier genes that protect
or fail to protect an individual from CF lung and airways
disease progression [7]; (b) additional genes that cause
predisposition to CF lung and airways disease progression
[7,8]; and/or (c) CFTR’s known role as a regulator of other
conductances and cellular processes [4]. Better under-
standing of ΔF-CFTR biology, physiology and lung and
airways defects is critical, because the majority of the asso-
ciated pathology and corresponding mortality of CF
occurs in the pulmonary system.
One of the hypothesized and more viable methods to treat
CF is by gene correction or protein replacement [9,10]. The
goal is to introduce or replace the defective copy of CFTR
with a functional wild-type (WT) copy that could generate a
normal mRNA and a functional protein. Promising methods
of introducing the WT-CFTR gene is via lipid- or virally-
mediated transduction [9,10]. Barriers to these methods are
currently being overcome [9,10]. One overwhelming prob-
lem is the lack of an animal model that displays the charac-
teristic lung pathology seen in humans that a gene-bearing
vector seeks to correct [9,10]; however, recent work on por-
cine and ferret animal models of CF is promising [11-13].
Work described herein introduces another concept that
needs to be addressed in the context of these putative ther-
apies: What if the mutant CFTR protein interacts with and
affects the processing and function of the introduced WT-
CFTR? A dominant negative-like effect of the endogenous
ΔF-CFTR could also limit the effect of a WT-CFTR gene or
protein correction or a CF corrector drug in a target cell.Recent work has focused on examination of WT-
CFTR and mutant CFTR biogenesis, trafficking, and
functions within CFTR’s native environment, the polar-
ized airway epithelial cell. In this light, we published im-
portant methods on transient transfection of CFTR into
non-polarized and polarized epithelial cells [14]. We also
showed that WT-CFTR processing in epithelial cells is
more efficient than first suggested in heterologous cell
systems over-expressing CFTR [15]. In the context of
this work, we observed curious results that led us to test
the hypothesis that mutant forms of CFTR can interact
with and inhibit WT-CFTR function in airway epithelial
cells. We present results herein with in vivo and in vitro
approaches that support the hypothesis that ΔF-CFTR
inhibits WT-CFTR in a dominant negative-like manner
when co-expressed together in the same epithelium.
This hypothesis is germane to two different fields of
CF research. The former relates to whether defects or
predispositions to dysfunction are found in the CF het-
erozygous carrier. The latter involves whether or not
CFTR exists within an oligomeric protein complex in
epithelial cells as a monomer or a multimer. Throughout
the clinical study of endpoints in CF, partial defects or
dysfunction in the CF heterozygous carrier have been
observed. However, because the CF carrier does not
present with full progressive CF disease in the GI tract
or in the lung and airways and because genotypes were
not fully defined in these older studies, CF carriers have
not be studied deeply or as a full study group compared
to homozygotes or WT controls. Heterozygous cell mod-
els are also not available for similar reasons. However,
partial loss in the volume of sweat or in rate of secretion
in response to agonists has been documented in CF het-
erozygotes versus WT controls [16,17], whereas CF
homozygotes fail to respond to agonists. Graded differ-
ences in sweat [Cl-] amounts were observed that yielded
three statistically different groups in a continuum be-
tween CF homozygote patients, CF heterozygote car-
riers, and WT controls. Clinical endpoints have noted
statistically valid predispositions to pancreatitis, rhinitis
and sinusitis, allergic bronchopulmonary aspergillosis,
and airway hyper reactivity in CF heterozygotes [18-21].
The latter predisposition to airway reactivity has been
studied for several decades and have driven asthma
geneticists to document prevalence of CF gene muta-
tions in populations with severe asthma prevalence [18].
Additional studies were found in our literature review,
but only the subset cited above studied all three geno-
types. Nevertheless, the listed observations above pro-
vided a compelling rationale for studying wild-type
CFTR and mutant CFTR interaction as a possible cause
of heterozygote dysfunction.
A multitude of studies focusing on CFTR protein
biochemistry have concluded that CFTR is a monomer
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largely performed in heterologous cell over-expression
systems and was arrived at before the identification of
CFTR binding partners at the N- and C-termini [27-34].
In particular, the identification of the PDZ-binding motif
on the extreme C-terminal end of the carboxy-terminal
tail and epithelial PDZ binding proteins such as EBP-50
(NHERF-1), E3-KARP (NHERF-2), CAP-70, and CAL
among others have made many investigators re-think this
conclusion [35-41]. This is particularly true in the context
of the epithelial cell, where a single CFTR monomer could
associate with a second CFTR monomer or with a larger
number of CFTR monomers via PDZ-dependent contacts.
Several investigators have shown that association with
PDZ binding proteins affect CFTR Cl- channel function,
trafficking and localization [36-41]. Bear and colleagues
have recently assessed the monomer versus multimer
issue with CFTR expressed in different cell models and
subjected the CFTR-enriched lysates to sucrose gradient
analysis under non-denaturing and denaturing conditions
[22]. Their conclusion was that CFTR existed as a mono-
mer, as a dimer, and, possibly, in higher order multimers,
but that a monomer was sufficient for Cl- channel activity.
Moreover, Naren and colleagues have shown in heterol-
ogous and epithelial cells that CFTR is a multimer that
self-associates by a mechanism that does not appear to in-
volve the PDZ motif in the C-terminus [23]. In addition,
Cormet-Boyaka et al. characterized a trans-complementation
mechanism where fragments of CFTR could rescue
CFTR folding mutations [33]. They state that masking
the mutated region of the CFTR polypeptide with a cor-
responding WT fragment could cause the mutant to es-
cape the ER [32,33]. Zerhusen et al. showed that a CFTR
concatemer acted in a similar manner to a single CFTR
protein, arguing for possible cooperation of multiple
CFTR proteins to form a functional channel [27]. In their
discussion, these authors hint at the idea that mutant
CFTR proteins could affect WT-CFTR [22,23,27,32,33].
The same has been studied recently for mdr P-glycopro-
teins, where monomeric and multimeric conclusions have
been drawn [28]. Therefore, it is still an open question
whether CFTR assembles as a multimer through: (a) self-
association; (b) as an oligomeric complex; or (c) resides as
a multimer within an oligomer. Nevertheless, there are
compelling data from our laboratory and from others that
multiple CFTR polypeptides can interact by either or both
mechanisms in epithelial cells.
In the study herein, our data address both issues of
heterozygote dysfunction and CFTR multimerization by
assessing the dominant negative-like inhibition of WT-
CFTR by ΔF-CFTR in human airway epithelial cells.
Critically, the effect is specific to the ΔF-CFTR mutant.
The results also speak to the need to overcome mutant
CFTR effects on WT-CFTR introduced by emergingtherapeutic methods. We show that ΔF-CFTR, when co-
expressed with wild-type CFTR by multiple methods,
inhibits WT-CFTR processing and, therefore, function in
epithelial cells but not in heterologous cells.
Methods and materials
Cell culture
All cell culture substrates (plates, flasks, and filters
supports) for epithelial cells were coated with 1:15 diluted
Vitrogen 100 solution in Ca/Mg Free Dulbecco’s PBS (Life
Technologies/Invitrogen). The diluted Vitrogen solution is
added, allowed 2–3 min to coat the substrate, and is then
removed for air drying in a sterile hood. CALU-3 (a human
non-CF submucosal airway serous cell line endogenously
expressing CFTR) [42] and HEK293T (a human embryonic
kidney heterologous cell model over-expressing the large T
antigen to amplify cDNA expression) [43] were grown in
Minimal Essential Medium (MEM) with 10% heat-
inactivated fetal bovine serum (Life Technologies/Invitro-
gen), 6 ml of penicillin-streptomycin 100× solution (penicil-
lin 100 U/ml and streptomycin 100 μg/ mg final; Life
Technologies/Invitrogen), 6 ml of 200 mM L-glutamine
100X solution (2 mM Final; Life Technologies/Invitrogen),
and 2 ml of fungizone solution (amphotericin B, 1 ug/ml
final; Life Technologies/Invitrogen). The IB3-1 cell line
(derived from a CF human bronchus expressing the
ΔF508 and W1282X mutant forms of CFTR) was grown
in LHC-8 media without gentamycin (Biofluids) supple-
mented with 5% heat-inactivated fetal bovine serum,
6 ml of penicillin-streptomycin 100x solution (penicillin
100 U/ml and streptomycin 100 μg/mg final), 6 ml of
200 mM L-glutamine 100X solution (2 mM final), and
2 ml of fungizone solution (amphotericin B, 1 ug/ml
final).
Culture of polarized epithelial cell monolayers
CALU-3 non-CF human epithelial cells (parental, G418-
resistant lacking mutant CFTR, and G418-resistant expres-
sing mutant CFTR; see selection procedure below) were
seeded onto coated 6.5 mm diameter polyester Transwell
Filters (Corning-Costar, Corning, NY) at 1 × 106 cells per
insert. For these cell monolayers, a measured transepithelial
electrical resistance (RTE) of > 2,000 Ω•cm
2 was achieved
routinely and sufficient to perform the subsequent Ussing
Chamber transepithelial Cl- secretion assays.
Transient transfection of non-polarized epithelial cells
These methods have been published previously [14]. How-
ever, co-transfection of wild-type and mutant CFTR
cDNAs was a novel feature of this study to simulate a
“heterozygous” cell. The methods of LipofectAMINE
PLUS-mediated transient transfection were similar; how-
ever, the DNA combinations were varied in the following
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grown in a 10 cm diameter coated culture plate:
 EV or Empty Vector = 6.75 μg of pcDNA 3.1
plasmid DNA devoid of CFTR cDNA
 WT-CFTR-bearing Vector = 0.75 μg (Balance
“backfilled” with 6 μg of empty vector or EV)
 ΔF-CFTR-bearing Vector = 0.75 μg (Balance
“backfilled” with 6 μg of EV).
Note below that the amount of ΔF-CFTR was increased
in a titration to determine how much ΔF-CFTR vector
needed to be transfected to make ΔF-CFTR protein that
was equivalent to WT-CFTR because of the dramatically
reduced protein half-life of this ER retention mutant
[44,45]. Thus, in other transiently transfected cultures, a
mixture of WT-CFTR and ΔF-CFTR-bearing vector was
co-expressed in the same cells in the following mixtures:
 1×WT with 1×ΔF = 0.75 μg WT, 0.75 μg ΔF, 5.25 μg
EV
 1×WT with 2×ΔF = 0.75 μg WT, 1.5 μg ΔF, 4.5 μg
EV
 1×WT with 4×ΔF = 0.75 μg WT, 3.0 μg ΔF, 3.0 μg
EV
 1×WT with 8×ΔF = 0.75 μg WT, 6.0 μg ΔF; 0 μg EV
These ratios were used for the IB3-1 CF and HEK-293 T
cells transfected transiently. For G551D-CFTR experi-
ments, the same amounts of G551D-CFTR bearing plas-
mid were used as a substitute for ΔF-CFTR. These DNA
combinations were incubated with PLUS reagent in
OptiMEM-1 serum-free medium for 15 min at room
temperature. After the first incubation, LipofectAMINE
reagent from a separate tube was mixed with the PLUS
reagent-primed plasmid DNA combinations. The complete
transfection cocktail was incubated for another 15 min at
room temperature. During the incubation periods, the cells
were washed 3X with Opti-MEM-1 medium to remove all
serum and to sensitize the cells to the serum-free medium.
After the final wash, the transfection cocktail was brought
up to a final volume of 6 mls from a mixing volume of
1 ml. The cells were then incubated for 6 h at 37°C
in the humified CO2 incubator. After the 6-h incuba-
tion, the cells were washed 2× with Opti-MEM and
1× with FBS containing media to remove excess lipid-
DNA complexes. The cells were re-fed 24 h after
transfection and studied for CFTR biochemistry and
function 48 h post-transfection.
Transient transfection of HEK293T heterologous cells
Similar methods were followed to those described above
with the notable exception that Effectene reagent (Qiagen)
was used for HEK293T cells [14]. This reagent wasfound to be toxic to all epithelial cell models but
ideal for HEK-293 cells [14]. Surprisingly, there was
minimal toxicity to HEK-293 cells while a transfection
efficiency of 90-95% was routine. Enhancer reagent
was added to OptiMEM-1 medium along with the
same DNA combinations above. The mixture was
incubated for 10 min at room temperature. After the
initial incubation, 24 μl of Effectene reagent was
added to each tube, followed by 10 min incubation at
room temperature. During the incubations, the cells
are washed 3× with Opti-MEM. After the final wash,
all media is removed from the cells, and transfection
cocktails are brought up to a 6 ml volume and added
to the culture dishes. The cells were incubated in
transfection cocktail for 4 h at 37°C in the humified
CO2 incubator. After the 4-h incubation, the cells
were washed 2× with Opti-MEM and 1× with FBS
containing media. The cells were re-fed 24 h after
transfection and studied for CFTR biochemistry and
function 48 h post-transfection.
Stable transfection and selection of “heterozygous” cells
Similar LipofectAMINE PLUS-based methods were used
as above. Vector bearing ΔF508-CFTR cDNA was transi-
ently transfected in combination with the pcDNA 3.1
vector with a G418-resistance gene cassette to confer
antibiotic resistance into the non-CF airway epithelial
cell lines, CALU-3. CALU-3 cells grow as ‘islands’ of
cells that eventually grow and fuse together as a conflu-
ent monolayer. The cells were transfected as small
islands dispersed throughout the culture dish. The cells
were re-fed 24 h after transfection and cultures were
allowed to grow until the islands grew much larger but
were still not yet fused together as a confluent culture.
After 7–10 days of culture as described above, MEM
complete media was added that was also supplemented
with 700 μg/ml of genetic in (G418) to select stably
transfected CALU-3 cell islands. The cells were washed
with PBS and fed G418-containing MEM complete
medium every other day that was made fresh and fil-
tered to keep G418 activity high in the cultures. The ma-
jority of the cell islands died; however, some cells within
islands lived and began to form isolated colonies. These
‘island colonies’ were then selected using cloning rings
(the reason for using 10 cm diameter dishes was that
sterile cloning rings could be inserted by simply lifting
the lid of the dish). The cloning rings were dipped in
sterile, autoclaved vasoline gel to allow them to adhere
to the bottom of the plate. Once these colonies grew to
confluence within the cloning ring, the clonal ‘island
colony’ was transferred to a 24 well plate for further
expansion. They were then expanded further into flasks
as well as frozen in micro-aliquots to have the earliest
possible passage following selection cryopreserved.
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Published methods were followed [15]. Cells were washed
1X with CaMg containing PBS. The cells were kept at 4°C
during washes. The cells were subsequently lysed in
“Radioimmunopreciptiation Assay” (RIPA) Buffer contain-
ing NP40 (1%), sodium deoxycholate (.5%), SDS (0.1% at
pH 8.0), and sodium chloride (150 mM) supplemented
with Protease Inhibitor Cocktail (Roche). Samples were
homogenized and incubated for 30 min at 4°C. The lysates
were then centrifuged at 14,000 g at 4°C for 20 min. The
supernatants were then collected and protein concentra-
tions calculated using the BCA Protein Assay Kit and a
microplate reader. Immunoprecipitations were performed
using Protein A Agarose and the anti-CFTR Ab targeted
to the NBD-1/R region of CFTR (Bedwell/Collawn) with
at least 800 ng of lysate supernatant. The supernatants
were added to the Ab/Protein Agarose Solution and
allowed to incubate at 4°C for 2 h or overnight on an end-
over-end shaker (rotator). Samples were then centrifuged
at 14,000 g for 2 min and the supernatant removed from
the pelleted agarose beads. RIPA buffer (750 μl) was then
added to the beads, centrifuged for 2 min at 14,000 g, and
the supernatant removed. This was repeated 2 times. On
the final wash, the pelleted beads were washed with 750 μl
PKA Buffer. Two μl of PKA catalytic subunit and 10 μl
[γ-32P] ATP were added to phosphorylate the bound CFTR
to make it detectable with phosphor-imaging technology.
The samples were then allowed to incubate for 45 min at
30°C. After the incubation, the cells were washed 3X with
RIPA buffer at room temperature. Excess RIPA buffer was
then removed from the beads. Thirty-five μl of 2X sample
buffer with β-mercaptoethanol was added to the samples
and incubated at 37°C for 15 min. Samples were then run
on a 6% Tris Agarose gel at 150 V for 90 min, dried in a
gel dryer, and analyzed on the PhosphorImager.
Voltohmeter open-circuit and ussing chamber short-
circuit current measurements of monolayer electrical
properties
RTE was measured using the Millipore MilliCell ERS
Voltohmeter that uses Ag-AgCl pelleted chopstick elec-
trodes. The RTE was monitored on a daily basis and was
used as an indicator of the level of maturity of the
monolayer. When monolayers had matured and reached
a RTE plateau (> 1,000-2,000 Ohms), Ussing chamber
recordings of the short-circuit currents were performed.
Ussing chamber experiments were performed as
described previously [46]; however, they were designed
to activate and monitor CFTR Cl- currents in accord-
ance with recent published studies. Recordings were per-
formed in OptiMEM-1 reduced serum medium or in
Ringers enriched with bicarbonate on CALU-3 non-CF
airway epithelial cells grown as monolayers (a submuco-
sal gland serous cell model with abundant endogenousCFTR expression) that were or were not stably trans-
duced with ΔF508-CFTR. Amiloride (10 μM) was added
to the apical solution to inhibit any residual ENaC-
mediated Na+ currents which were negligible in these
cell models grown under these conditions. Then, forsko-
lin (2 μM) was added to both sides of the cell
monolayers to increase cyclic AMP and stimulate CFTR
Cl- conductance. To maximally activate CFTR Cl- conduct-
ance in these monolayers, genistein (50 μM) was added to
both sides of the monolayer. In some experiments, gliben-
clamide (glyburide, 50 μM) was added to inhibit the
CFTR-mediated Cl- conductance (data not shown). Magni-
tude of the forskolin- and genistein-activated Cl-
conductance was compared statistically between parental
or G418-resistant clones CALU-3 cells that lacked
ΔF508-CFTR versus those that possessed ΔF508-CFTR.
SPQ halide fluorescence assay of halide transport
The SPQ assay was used to detect the amount of active
CFTR Cl- channels that are functional at the plasma
membrane of the transiently transfected cells. It has
been used previously by our laboratory in published
papers [47]. The SPQ fluorescent dye is sensitive to
halides, some of which quench the dye’s fluorescence
(iodide, chloride) and some of which do not (nitrate).
The cells are seeded onto a glass coverslip. After a 24 h
period, the cells were then transiently transfected with
the CFTR cDNAs. Twenty-four hours after initiation of
transfection, the cells were placed in media containing
the SPQ dye (10 mg/ml) for overnight incubation. After
another 24 h, the cover slips were taken and placed on
the fluorescence scope (the cover slips actually form the
bottom of the flow chamber). Twenty-five to 30 individ-
ual cells were selected based upon the intensity of their
fluorescence, which denotes the efficiency of SPQ dye
uptake. Their fluorescence is then measured and
recorded. The SPQ fluorescence protocol is as follows.
The cells were placed in the perfusion chamber and
exposed to 3 different buffers: (1) NaI buffer (iodide enters
the cells and quenches SPQ fluorescence; (2) NaNO3
buffer (nitrate reverses this gradient and allows the iodide
to passively diffuse out of the cells and unquenches the
fluorescence); (3) NaNO3 buffer with a cAMP agonist
cocktail (100 μM isobutylmethylxanthine (IBMX), 10 μM
forskolin, and 200 μM dibutyryl-cAMP, 8-bromo-cAMP
or CPT-cAMP) to stimulate CFTR Cl- conductance and
stimulate additional iodide efflux from the cell; and
(4) NaI buffer without agonists, to wash out and reverse
agonist effects as well as re-quench SPQ fluorescence. The
reversibility and re-quenching is also a good indicator of
the viability of and level of dye within the cells throughout
the entire experiment. The relative background for each
cover slip was subtracted from the recorded arbitrary light
unit measurements. The resultant data points are analyzed
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which establishes the baseline.
Nasal potential difference (NPD) assays on two different
cf mouse models
NPD assays were performed as described previously but
were designed to specifically study and activate CFTR
maximally. We performed experiments on all three CFTR
genotypes in each mouse model. One mouse model was
the ΔF508-CFTR mouse developed by Thomas and co-
lleagues [48]. The second mouse model was the UNC
knockout mouse that was corrected in the gastrointestinal
tract by complementation with a fatty acid binding protein
(FABP) promoter-driven CFTR construct. The lung and
airways remain null for CFTR (a generous gift from Dr.
Jeffrey Whitsett, M.D., Ph.D. to the UAB CF Center, [49].
Amiloride (50 μM) was added in a standard Lactated
Ringers in step 1 of the assay to inhibit all Na+ absorptive
pathways. In the continued presence of amiloride, a low
Cl- (6 mM) solution was perfused to gauge Cl- permeabil-
ity of the nasal mucosa epithelium. Wild-type and hetero-
zygous animals possessed a low Cl- response, while
homozygous animals did not. In the presence of amiloride
and in a low Cl- solution, adenosine and salbutamol
(100 μM each) were added together to increase cyclic
AMP maximally via their respective G protein-coupled
receptors that engage adenyl cyclase. Isoproterenol
(Isoprel™) or albuterol (salbutamol) alone were not enough
to maximally stimulate CFTR. It was adenosine together
with a β-adrenergic agonist that gave us consistent cyclic
AMP induction of CFTR above and beyond the low Cl- re-
sponse. This modification was done based on the work of
Clancy and colleagues on adenosine regulation of CFTR
in mice and humans [50,51]. The change in PD, in the
negative direction (hyperpolarization) during the low Cl-
phase and adenosine and salbutamol (cyclic AMP) phase
of the recordings, was quantified from the strip-chart
records. Ussing chamber assays were performed as
described above on primary mouse tracheal epithelial cell
monolayers derived from these mice.
MTE monolayer culture and ussing chamber analysis
After analysis of in vivo CFTR function by nasal PD in
the three CFTR genotypes in each mouse model, tra-
cheae were excised by surgery in anesthetized mice and
were kept separated as to genotype. Tracheae were first
washed in a CaMg-free PBS with 5X penicillin/strepto-
mycin (500 U/ml penicillin, 500 μg/ml streptomycin).
Tracheae were then washed in a series of dishes contain-
ing CaMg-free DMEM/F12 medium with 5X penicillin/
streptomycin. Excess tissue was removed from the tra-
cheae, and they were filleted open down the midline
from the laryngeal cartilage to its base. The dissection
was performed in the above DMEM/F12 DissectionMedium. The filleted tracheae were then placed in
CaMg-free DMEM/F12 medium with 2X penicillin/
streptomycin and 1 μg/ml protease type XIV and 0.1 μg/ml
DNase I on ice. The tracheae were digested at 4°C over-
night in this Digestion Medium without agitation. After the
18 h overnight digestion in the cold, tracheae were inverted
in the tubes 15X to maximally dissociate cells. FBS (20%)
was then added to inactivate the enzymes, and the disso-
ciated cells were placed into a separate tube on ice. The
digested tracheae were then washed (with 15X tube in-
version again) in mouse tracheal epithelial (MTE) cell
Monolayer Maturation - CaMg-containing DMEM/F12
medium supplemented per 500 mls of medium with 20%
FBS (Life Technologies, Certified and Heat-Inactivated), 2X
Pen/Strep, 5 mls of L-glutamine (from 100X stock), 2 mls
of hydrocortisone (from 10 ml stock solubilized in ethanol,
Becton-Dickinson), 2 mls of endothelial cell growth supple-
ment (ECGS from 10 ml stock, Becton-Dickinson), 2 mls
of bovine pituitary extract (BPE from 10 ml stock, Becton-
Dickinson), and 4 mls of insulin-transferrin-selenium (ITS
from 20 ml stock, Becton-Dickinson). Washes were col-
lected and placed on ice. Then, the tracheae were exposed
to fresh Digestion Medium for 1 h at 37°C. After the sec-
ond digestion, the tubes were inverted 15X, FBS (20%) was
added to inactivate the enzymes, dissociated cells were col-
lected in a separate tube, and washes with standard culture
medium were performed as above. Four separate sets of
tubes (two digestions, two washes) were centrifuged for 3–
5 min to pellet any and all cells. Pellets were then obtained
from all 4 phases of the MTE cell isolation. Then, cells were
combined (still separated as to CFTR genotype), pelleted
and resuspended in a minimal volume (50–100 μl per filter
support). Four filter supports can be seeded per 1 trachea.
Filter supports were coated with CellTak and with a 1:10
diluted Vitrogen 100 solution (in CaMg-free PBS) that also
contained 1 mg human fibronectin (Becton-Dickinson)
added into a 50 ml total volume one day prior to seeding.
The cell seeding day was deemed Day 0. Cells were allowed
to attach over an initial 3-day period with medium bathing
both sides of the filter support. Then, on Day 3, medium
was removed and only the basolateral (bottom) side of the
filter support was fed to initiate air-fluid interface (AFI) cul-
ture. MTE monolayers were maintained in this way until
leak of medium was no longer observed from the bottom
to the top of the filter support. Visual inspection of the cells
on the filter support when no leak was observed showed
“doming” and “ridging” of a confluent monolayer. After this
point in monolayer culture, RTE and VTE were monitored
with a Voltohmeter (Millipore or World Precision Instru-
ments). RTE above 1,000 Ω•cm
2 and a significant negative
VTE were then measured on or after Days 8–10. We per-
formed Ussing chamber analysis when the electrical para-
meters had plateaued in open-circuit measurements and
did not increase further.
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Explanation of quantification and statistical analysis of
the data generated in all assays was explained in the
context of the specific methods presented above.
Results
Early Evidence of ΔF508-CFTR inhibition of wild-type
CFTR function
As a collaborative effort among multiple authors and la-
boratories involved in this study, a study was published in
which optimization of transient transfection of polarized
epithelial cell monolayers was performed [14]. The found-
ing context of this work was that CFTR biogenesis, traf-
ficking and function would be best studied in its native
environment, the polarized human airway epithelial cell.
During these studies, we observed that ΔF-CFTR expres-
sion in epithelia inhibited WT-CFTR driven cyclic AMP-
activated Cl- channel activity, monolayer maturation, and
regulation of chemokine release. These observations pro-
vided the rationale for designing and undertaking the
studies described below.
Is the expression of wild-type cftr altered by co-
expression of ΔF508-CFTR?
To determine whether the processing of WT-CFTR is
affected by the presence of ΔF-CFTR, we co-expressed
the WT and mutant forms of CFTR in IB3-1 CF human
airway epithelial cells that are null for detectable en-
dogenous CFTR protein (Figure 1A). Examination of
immunoprecipitated and PKA-decorated proteins on a
6% SDS-PAGE gel showed that processing of a fixed
amount of WT-CFTR was altered by increasing amounts
of ΔF-CFTR. In native epithelia, CFTR is immunopreci-
pitated as two major forms. “C band” is a broad band be-
tween 160–180 kDa that is the maturely glycosylated
form of CFTR that successfully traffics through the
secretory pathway to the apical plasma membrane. C
band is the only form found when exogenous WT-CFTR
was expressed alone in IB3-1 cells. ”B band” is a tighter
immaturely glycosylated band between 140–150 kDa
that is an ER form of CFTR. It is a single band in native
epithelia and a doublet of bands in HEK-293 cells (see
below). B band is the only band observed when exogen-
ous ΔF-CFTR was expressed alone IB3-1 cells. In
Figure 1A, as the amount of ΔF-CFTR cDNA was
increased in the presence of a fixed amount of WT-
CFTR cDNA, there was decreased processing of the C
band of WT-CFTR protein. Inhibition of C band forma-
tion was most notable when 4-8-fold more ΔF-CFTR
plasmid was co-transfected versus WT-CFTR (refer to
both examples in Figure 1A for different examples of the
same dominant negative-like effect. We speculate that
this is due to the increased rate of degradation in the ER
of ΔF-CFTR versus WT-CFTR [44,45]. However, whenthe same co-transfection experiment was performed in
the heterologous human embryonic kidney cell line,
HEK-293 T, over-expression of ΔF-CFTR was without
effect on WT-CFTR processing (Figure 1B). These
results suggest that CFTR processing may be different in
epithelial cells versus heterologous cells and that
epithelial-specific accessory proteins may be essential for
driving this ΔF-CFTR inhibitory interaction with WT-
CFTR.
Is this dominant negative-like effect of ΔF508-CFTR on
WT-CFTR dependent upon Its PDZ motif?
To assess specificity of this ΔF-CFTR/WT-CFTR inter-
action, we co-expressed ΔF-CFTR with a fixed amount
of ΔTRL-CFTR, a CFTR variant lacking the C-terminal
PDZ binding motif but that processes efficiently through
the Golgi to the plasma membrane [52]. The CFTR PDZ
motif is critical for CFTR interactions with PDZ binding
proteins such as EBP50 (NHERF), E3KARP, CAP-70,
CAL, etc., connects CFTR to larger macromolecular
complexes in organelle and plasma membranes, and
influences CFTR function [35-41,53]. In contrast to
dominant negative-like effects on WT-CFTR by ΔF-
CFTR, increasing amounts of ΔF-CFTR failed to affect
the maturation of ΔTRL-CFTR in IB3-1 CF human air-
way epithelial cells (Figure 1C). Summary data is also
presented from multiple experiments (Figure 1C). ΔF-
CFTR was also without effect on ΔTRL-CFTR in HEK-
293 T cells (data not shown). These results suggest that
the PDZ motif of CFTR is critical to the inhibitory influ-
ence of ΔF-CFTR on WT-CFTR at the level of the ER.
Is this a specific and exclusive interaction between
ΔF508-CFTR and WT-CFTR?
We wished to take addition steps to provide specificity
and exclusivity for this macromolecular complex and
PDZ motif-driven ΔF-CFTR/WT-CFTR inhibitory inter-
action, we expressed increasing amounts of G551D-
CFTR with a fixed amount of WT-CFTR. We observed
only accumulating amounts of C band that did not ap-
pear to saturate during the co-expression of this mutant
and WT-CFTR (Figure 2A). It is important to under-
score the fact that G551D-CFTR is not an ER retention
mutant but rather is processed normally to the plasma
membrane. Rather, G551D-CFTR is a dysfunctional Cl-
channel because ATP binding and gating to its NBDs is
impaired. This is why the CFTR potentiator drug, VX-
770 (ivacaftor, Kalydeco) [54] is markedly effective in
G551D-CFTR patients, while the CF corrector drug, VX-
809, corrects/rescues ΔF-CFTR from ER quality control
and is without effect on G551D-CFTR patients [55,56].
We also wished to determine whether this dominant
negative-like effect of ΔF-CFTR was not non-specific to
other glycosylated membrane proteins. The epithelial
Figure 1 Co-expression of increasing amounts of ΔF-CFTR alters the processing of WT-CFTR but not ΔTRL-CFTR in IB3-1 CF epithelial
cells. ΔF-CFTR does not influence WT-CFTR in heterologous human HEK293T cells. A. IB3-1 CF bronchial epithelial cells transfected transfected
with a fixed amount of WT-CFTR and increasing amounts of ΔF-CFTR. Two different examples are shown, a full titration and a partial experiment
imaged by different methods. B. HEK293T cells were transfected with the same mixtures and CFTR detected biochemically. C. The relative effect
of ΔF-CFTR on the processing of a fixed amount of ΔTRL-CFTR in the presence of increasing amounts of ΔF-CFTR provided in a typical blot and
effect of ΔF-CFTR on both fully processed CFTR constructs (WT and ΔTRL) was quantified and graphed.
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http://www.biomedcentral.com/1472-6793/12/12P2X4 purinergic receptor calcium entry channel also has
immature (~40 kDa) and maturely glycosylated (60–
65 kDa) forms and robust expression in both CF and non-
CF human airway epithelial cells [57]. P2X4 expression is
robust in Western blot analysis and no difference inexpression of either form of the receptor channel was
observed with increasing amounts of ΔF508-CFTR plasmid
expression (Figure 2B). These data, along with other internal
controls above in Figure 1, suggest that ER stress is not a
















































Figure 2 Confirming the specificity of the dominant negative-
like effect of ΔF-CFTR on WT-CFTR in native IB3-1 CF bronchial
epithelial cells. A. Similar co-expression biochemical experiments
with G551D-CFTR and WT-CFTR. B. Increasing amounts of ΔF-CFTR
do not affect the maturation and processing of a different
glycosylated membrane protein, the purinergic receptor channel,
P2X4.
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ΔF-CFTR?
To complement the biochemical experiments above, we
also assayed for CFTR Cl- channel function with the SPQ
halide efflux assay [47]. IB3-1 cells were co-transfected
with increasing amounts of ΔF-CFTR versus a fixed
amount of WT-CFTR as above. These cells were later
incubated with the halide-sensitive dye, SPQ, overnight in
medium prior to the experiment 2 days after transient
transfection. Cover slips of transiently transfected cells
were mounted into a perfusion chamber and bathed in so-
dium iodide (NaI) buffer to maintain quenching of SPQ
fluorescence. First, the cells were challenged with NaNO3
buffer, which dequenchs SPQ and assays for basal halide
efflux which is augmented by WT-CFTR expression.Second, a cocktail of cyclic AMP agonists (CPT-cAMP,
200 μM; forskolin, 2 μM; IBMX, 100 μM) was perfused
into the chamber in NaNO3 buffer to stimulate additional
CFTR Cl- channel activity (measured by increased halide
efflux). Mock and ΔF-CFTR-expressing cells failed to re-
spond to NaNO3 buffer alone or to the cocktail of cyclic
AMP agonists (Figure 3A). In contrast, WT-CFTR-
transfected cells responded markedly to both NaNO3 buf-
fer alone or to the cyclic AMP cocktail (Figure 2A).
However, in the co-expression experiments, increasing
amounts of ΔF-CFTR inhibited wild-type CFTR activity in
an apparent dose-dependent manner (Figure 3A). The
functional assay showed complete inhibition with 4:1 ΔF-
CFTR:WT-CFTR expression, while biochemical assays
showed complete inhibition with 8:1 ΔF-CFTR:WT-CFTR
expression. In contrast, similar experiments in the HEK-
293 T system showed no inhibition of WT-CFTR with in-
creasing amounts of ΔF-CFTR (Figure 3B). Taken together,
these data suggests that ΔF-CFTR interacts with WT-
CFTR during its processing and inhibits its functional
expression in the plasma membrane in a dominant
negative-like manner in human airway epithelial cells.
Are the processing and function of WT-CFTR altered
by stable expression of ΔF-CFTR in a polarized non-CF
human airway epithelial cell line that expresses endogen-
ous CFTR?
One potential problem of the co-transfection and co-
expression studies above was the necessity to transiently
transfect with large quantities of plasmid DNA and to
over-express ΔF-CFTR in order to inhibit WT-CFTR
processing and function. Again, we speculate that this is
likely necessary to overcome the increased rate of deg-
radation of ΔF-CFTR protein versus WT-CFTR protein.
However, to account for this issue and to approach this
inhibitory interaction differently, we employed the well-
characterized WT-CFTR-expressing airway epithelial cell
line, CALU-3, and stably transfected ΔF-CFTR into it,
generating several clones that were CF heterozygous cell
lines. We also chose the CALU-3 cell line because of its
high level of endogenous WT-CFTR expression and its
ability for form polarized cell monolayers when grown
on filter supports. Upon expansion and cryopreservation
of the clones, CFTR biochemistry was performed. Paren-
tal CALU-3 cells expressed the C band form of CFTR al-
most exclusively (Figure 4A); all clones stably expressing
ΔF-CFTR as an engineered heterozygous CF cell
expressed both B band and C band forms and with
reduced C band amounts in all clones. To assay for
CFTR Cl- channel function, we grew parental CALU-3
cells and ΔF-CFTR-expressing CALU-3 clones on per-
meable filter supports for Ussing chamber analysis of
short-circuit current (ISC). Monolayers with a transe-
pithelial resistance (RTE) at or above 1,000 Ω•cm
2 were
used in these experiments. In all experiments (Figure 4B
Figure 3 Co-expression of increasing amounts of ΔF-CFTR alters the function of WT-CFTR in IB3-1 CF epithelial cells but not in
HEK293T cells. A. IB3-1 cells are seeded on Vitrogen coated coverslips and transiently transfect in the manner previously described in Figure 1.
Twenty-four hours after transfection the cells are loaded with the halide sensitive dye, SPQ, overnight. The cells relative fluorescence is then
measured while incubated in three different buffers: NaI, NaNO3, and NaNO3 with cAMP agonists, and then back into NaI. B. HEK293T cells were
seeded on Vitrogen free coverslips and transfected, loaded, and measured as previously described in A.
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Figure 4 Stable Transfection of ΔF508-CFTR into CALU-3 non-CF epithelial cells alters the processing and function of endogenous WT-
CFTR. A. CFTR was IP’d from parental and stably transfected CALU-3 cells. The samples were then phosphorylated and resolved as described
previously. B. Parental and stably transfected CALU-3 cells were seeded on 6.5 mm Vitrogen coated permeable filter supports. The CALU-3
monolayers were then allowed to reach a transepithelial resistance (RTE) of 2,000 Ω•cm2 or above prior to experimentation. ISC is then measured
in response to 10 μM amiloride, 20 μM forskolin and 50 μM genistein added apically via an Ussing chamber. Typical traces are shown. C.
Summary analysis of parental and stably transfected CALU-3 cells ISC response to agonists.
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absorption which is minimal in this epithelial cell model.
Typical traces are shown for a parental CALU-3 cell
monolayer and for multiple stable clones expressing ΔF-
CFTR as an engineered heterozygous cell model co-
expressing WT-CFTR and ΔF-CFTR endogenously.
After amiloride pretreatment, forskolin (10 μM) was
added to stimulate CFTR-dependent Cl- secretion via
cyclic AMP. Then, genistein (50 μM) was added to open
any and all remaining CFTR Cl- channels in the apical
membrane. While parental CALU-3 cell monolayers
responded with an averaged 5 μA to forskolin and an
additional 1 μA to genistein in the presence of forskolin
(Figure 4B), stable clones co-expressing both WT-CFTR
and ΔF-CFTR endogenously responded only half as well
or less so than parental cell monolayers. Figure 4C pro-
vides the summary data for this Ussing chamber ana-
lysis. Taken together, these data show that equivalent
expression of WT-CFTR and ΔF5-CFTR endogenous to
an airway epithelial cell leads to inhibition of WT-CFTR
processing and, thus, function. Stable expression of both
forms of CFTR also obviated the need to express more
ΔF-CFTR in a transient transfection versus WT-CFTR
to observe the same dominant negative-like effect.
Is the function of WT-CFTR altered by ΔF-CFTR in WT-
CFTR/ΔF-CFTR heterozygous ‘carrier’ mice in vivo and
in vitro?
In vitro results above suggested a dominant negative-like
inhibition of WT-CFTR by ΔF-CFTR that was specific
to this most common ER retention folding mutant and
observed in native human airway epithelial cells. Studies
of human patients populations, where the WT (normal),
heterozygous carrier, and homozygous CF patients were
analyzed as separate groups, has shown three different
phenotypes for a given endpoint in past studies. We
wished to confirm our in vitro studies with in vivo nasal
potential difference (NPD) measurements in the ΔF508-
CFTR mouse [48]. A previous argument explaining par-
tial CF heterozygous defects was simply gene dilution
(e.g., 1 copy or allele of WT-CFTR versus 2 copies). As
such and in parallel, we performed NPD assays on a
bitransgenic CF mouse model generously provided to
our UAB CF Center Mouse Transgenic CORE by Dr.
Jeffrey Whitsett. This model is a CFTR knockout mouse
that is corrected in the gastrointestinal tract with a fattyacid binding protein (FABP) promoter-driven CFTR con-
struct [49]. In this bitransgenic mouse, however, the lung
and airways remain null for CFTR in the CF (−/−)
homozygous condition, the heterozygous mice have 1 al-
lele of CFTR (+/−), and the WT mice have two alleles of
CFTR (+/+). This is different from the ΔF-CFTR mouse,
where the WT mice will be WT/WT, the heterozygotes
will be WT/ΔF, and the homozygotes will be ΔF/ΔF.
Figure 5A shows typical NPD recordings from all 3
genotypes of the ΔF-CFTR mouse. Summary data that
includes and illustrates results from all mice studied in
shown in Figure 5B. Homozygous mice failed to respond
to the low Cl- solution, indicating a lack of Cl- perme-
ability in the nasal mucosa (Figure 5A and B). Homozy-
gotes also failed to respond significantly to cyclic AMP
agonists, adenosine (100 μM) and albuterol (salbutamol,
100 μM) (Figure 5A and B), although a small response
was noted a subset of mice (Figure 5B). In contrast, WT
mice within the ΔF-CFTR litters responded most vigor-
ously to both the low Cl- maneuver and to the dual cyc-
lic AMP agonists (Figures 5A and B). It should be noted
that the inclusion of adenosine was essential for these
studies, because Isoprel or salbutamol alone failed to
elicit as large or as reproducible responses in the NPD
assay. This modification was undertaken based on the
work of our colleague and collaborator, Dr. JP Clancy
et al., on adenosine regulation of CFTR [50,51]. Notably,
the ΔF-CFTR heterozygous mice had an intermediate
phenotype between WT mice and homozygous mice
with regard to the low Cl- and cyclic AMP-induced
responses (Figures 5A and B). Both hyperpolarization
responses were significantly less than WT. These in vivo
NPD data suggest that there is a decrement in CFTR Cl-
channel activity in heterozygous ΔF-CFTR carrier mice
versus WT mice when assessed across 6 different litters.
To derive closely paired in vitro data from these litters
of ΔF-CFTR mice, tracheae were excised from these
same mice in which CFTR NPD measurements were
performed previously to isolate and establish mouse tra-
cheal epithelial (MTE) cell monolayers grown on per-
meable filter supports in primary culture. Typical
recordings of ISC from all 3 genotypes from ΔF-CFTR
mouse model are shown in Figure 6A. Summary data
are shown in Figure 6B. As in in vivo NPD assays above,
WT MTE monolayers gave the most vigorous response
to forskolin and genistein, while heterozygous MTE
Figure 5 (See legend on next page.)
Tucker et al. BMC Physiology 2012, 12:12 Page 13 of 20
http://www.biomedcentral.com/1472-6793/12/12
(See figure on previous page.)
Figure 5 Nasal Potential Difference is altered by ΔF508-CFTR in WT- CFTR/ΔF508-CFTR Heterozygous mice. A. Nasal Potential Difference
Assays (NPD) were performed on the three genotypes of the ΔF508 mice: WT/WT, WT/ΔF, and ΔF/ΔF. NPD recordings were measured for each
genotype in the presence of normal Ringer’s solution, low Cl- ringer’s solution, and then low Cl- Ringer’s solution containing the cAMP agonist
salbutamol (100 μM) and adenosine (100 μM). B. Summary data of the results illustrated in A. C. Scatterplot representation of the NPD
measurements performed in the 3 genotypes of the ΔF508 mice.
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CFTR MTE monolayers failed to respond altogether
(Figure 6A and B). In a subset of recordings, glibencla-
mide (100 μM) inhibited the CFTR-mediated secretory
Cl- current (data not shown). Taken together, these data
are similar to results derived from in vivo NPD measure-
ments of the same mice and suggest that CFTR activityW T / W T
F
A
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Figure 6 WT-CFTR function is altered by ΔF508-CFTR in WT-CFTR/ΔF5
were seeded on Vitrogen coated filter inserts as previously described. On d
basolateral side but no media on the apical side. The RTE of the MTE mono
experimentation The MTE monolayer ISC current response to amiloride, fors
the ISC data of the three genotypes of the ΔF508 MTE monolayers. Homoz
ISC response was equal to zero.is partially attenuated in WT/ΔF heterozygous MTE
monolayers versus WT/WT controls.
Our parallel CF mouse model was the FABPxCFTR gut-
corrected UNC knockout mouse that remains null for the
lung and airways. In this case, the WTcontrols in these lit-
ters have 2 WT CFTR alleles, the heterozygous mice have
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above because ΔF-CFTR is not expressed in this mouse
model. Figure 7A shows typical NPD recordings from all
three CFTR genotypes in the Cincinnati bitransgenic mice.
In this case, 1 copy of CFTR appeared sufficient for full



















































































































Figure 7 WT-CFTR function is not affected by the null CFTR allele in t
Assays (NPD) were performed on the three genotypes of the mice: WT/WT
genotype in the presence of normal Ringer’s solution, low Cl- ringer’s solut
salbutamol (100 μM) and adenosine (100 μM). B. Summary data of the resu
of each mouse to low Cl- and cAMP agonists segregated to genotype.AMP agonist response between the WT and heterozygous
mice (Figure 7A,B,C). Homozygous mice failed to respond
to either maneuver (Figure 7A,B,C). Figure 7B is a scatter-
plot which represents the response of each mouse to low
Cl- and cAMP agonists segregated to genotype. Results


















































































he Cincinnati WT-CFTR/Null mice. A. Nasal Potential Difference
, WT/null, and null/null. NPD recordings were measured for each
ion, and then low Cl- Ringer’s solution containing the cAMP agonist
lts illustrated in A. C. Scatterplot which represents the NPD response
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function in an epithelium and in the absence of the ΔF
CFTR mutation.
We then established MTE monolayers from tracheae of
the same mice in the Cincinnati bitransgenic mouse litters.
Figure 8A shows representative ISC traces, Figure 8B shows
the summary data, and Figure 8C is a scatterplot which
represents the response of each mouse to low Cl- and
cAMP agonists segregated to genotype. Again, WTand het-
erozygous MTE monolayers had a similar response to both
forskolin and genistein. Homozygous MTE monolayers didA
W T / W T
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Figure 8 WT-CFTR function is not altered by the null CFTR allele in th
(MTE) were seeded on Vitrogen coated filter inserts as previously described
the basolateral side but no media on the apical side. The RTE of the MTE m
experimentation The MTE monolayer ISC current response to amiloride, fors
the ISC data of the three genotypes of the bitransgenic MTE monolayers.not respond to either agonist. Taken together, it is import-
ant to note that there is no decrement in overall WT-CFTR
function when the number of CFTR alleles is reduced from
2 to 1, suggesting again that ΔF-CFTR is a dominant nega-
tive inhibitor of WT-CFTR in airway epithelia.
Discussion
The results indicate that ΔF-CFTR alters the processing
and function of WT-CFTR in a dominant negative man-
ner when co-expressed in a CF human airway epithelial
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Tucker et al. BMC Physiology 2012, 12:12 Page 17 of 20
http://www.biomedcentral.com/1472-6793/12/12binding motif on its C-terminal end. Such an effect of ΔF-
CFTR on WT-CFTR could be conferred theoretically by
direct protein-protein interaction within a CFTR dimer or
multimer, the association of and regulation by accessory
proteins (i.e., PDZ binding proteins) for processing, traf-
ficking and function, and/or the association of and regula-
tion by necessary ER chaperones for protein folding.
With these three main biochemical factors impacting
upon CFTR biology in native epithelia, we present a sin-
gle unifying hypothesis to defend this effect in native
epithelia. First and foremost, this hypothesis is driven by
the fact that our observations hold in native epithelia.
Throughout our collective work over the last 15 years,
we continue to champion the idea that CFTR functions
differently and is processed differently in native human
epithelial cell platforms versus non-human or human
heterologous cell platforms. CFTR is a limited copy
mRNA and protein in native epithelia. Given the copious
data on CFTR monomer versus dimer versus larger mul-
timer, we are inclined to agree that CFTR is a monomer;
however, that does not mean that CFTR cannot be mul-
timeric in nature. Our central hypothesis speaks to this
idea and is predicated on the finding that CFTR resides
in a large macromolecular signaling complex that is
driven in part by its C-terminal PDZ binding motif. The
importance of the PDZ motif has been supported mainly
by data generated in native and polarized epithelial cell
platforms. There is also evidence in native epithelia for
PDZ-interacting proteins being involved in processing and
trafficking of CFTR [35-41,53]. Following on these suppo-
sitions in a logical manner, ER resident chaperones and the
supportive cytoskeleton would be involved actively in the
folding and placement of the multiple proteins within this
CFTR-resident macromolecular complex. Our hypothesis
also assumes that multiple copies (at least 2 copies) of the
CFTR protein are processed at the ER, trafficked through
the Golgi, and functional at the apical plasma membrane
within such a large complex. With similar supportive logic
and assuming multiple copies of CFTR per complex and
likely multiple complexes within each vesicle as cargo, a
ΔF-CFTR copy would attract chaperones that would iden-
tify the folding defect and attempt to retain this misfolded
ΔF-CFTR protein and associated proteins. More than one
ΔF-CFTR protein copy would amplify such attempted ER
retention. If copies of WT-CFTR are also present within
this large complex, they would be retained, snared or
‘caught up in’ this delF-CFTR retention in other parts of
the large complex. Finally, we believe that this dominant
negative effect would occur ahead of either Golgi-driven
trafficking to the plasma membrane or non-traditional
GRASP dependent trafficking that do not involve the com-
plex Golgi apparatus [58,59].
There are a number of proteins that are associated
with CFTR that could influence a dominant negativeinhibition of WT-CFTR by ΔF-CFTR. Two classes of
epithelial-specific accessory proteins likely involved are
ER resident chaperones and the PDZ binding proteins.
The heat shock family of proteins (HSP) is known to as-
sociate with CFTR at the level of the ER as a key group
of CFTR chaperones. All members of this family have
ATPase activity that is directly linked to their ability to
associate/disassociate with their protein substrate. Po-
tential candidates include HSP90, HSP70 and its cognate
HSC70 in conjunction with HSP40 and CHIP [60-67].
Recently, Balch and coworkers identified a ‘chaperone
trap’ for CFTR that included HSP40, HSP70 and HSP90
[67]. The latter HSP is known to interact with both WT-
CFTR and ΔF-CFTR and exists in a dimeric state. A
CFTR dimer could conceivably form through an HSP90
dimer at least transiently during CFTR biogenesis in the
ER. HSP70 is a less studied protein in CF; however, it
does bind CFTR. Its cognate relative, HSC70, is better
understood. HSC70 mediates CFTR degradation in the
ER through its interaction with HSP40 and CHIP [64].
HSC70’s association with CFTR and other protein sub-
strates is regulated by its fellow chaperone, Hdj-2, an
HSP40 family member [64]. In addition, CHIP, as a co-
chaperone, binds the HSC70/Hdj-2 complex via one of
three tetratricopeptide repeat (TRP) domains. This inter-
action inhibits the ATPase activity induced by Hdj-2 on
HSC 70 and prolongs the interaction of CHIP with
HSC70 and with the nascent CFTR peptide. Moreover,
CHIP has 3 TRP domains and could bind at least 3
CFTR/HSC70/Hdj-2 complexes [64] and target all to the
degradation pathway if one or more of the CFTR poly-
peptides being processed bore the ΔF-CFTR.
The second class of proteins likely involved in the
dominant negative interaction are the PDZ binding do-
main family of proteins that have the class 1 PDZ
domains which recognizes the QDTRL sequence in the
end of the CFTR C terminus. Candidates include CAL,
EBP50/NHERF-1, E3KARP, and CAP70 that likely influ-
ence both trafficking and anchoring of membrane pro-
teins like CFTR and that may be more deeply involved
in the ER processing than described previously
[35-41,53]. CAL or CFTR-associated ligand is a Golgi
resident PDZ protein which can prevent CFTR from
reaching the plasma membrane. CAL has only one PDZ
domain but exist in a homomultimeric state and could
tether multiple CFTR polypeptides together. EBP-50,
ezrin-binding protein 50 or Na/H exchange regulatory
factor 1 (NHERF-1) has two PDZ binding domains
which could, in theory, tether nascent ΔF-CFTR and
WT-CFTR polypeptides together if co-expressed in the
ER. CAP70, CFTR-associating protein 70, has 4 PDZ
domains and 3 of those domains bind CFTR with signifi-
cant affinity in the order, 3 > 1 > 4. This protein could
also bind up to three CFTR molecules and transport
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proteins to the degradation pathway if one or two of the
three CFTR polypeptides possessed the ΔF-CFTR muta-
tion. We hypothesize that chaperones, co-chaperones,
and PDZ binding proteins resident in the ER may all
play a significant role in the ΔF-CFTR/WT-CFTR inhibi-
tory interaction during processing in airway epithelia.
Our finding and the associated CFTR biology in native
epithelial cells has profound implications regarding the
development of efficient therapeutic methods to correct
or replace ΔF-CFTR in vivo. Although the understand-
ing of CFTR biology has advanced significantly in recent
years, there is much still poorly understood regarding
the processing and function of CFTR in native epithelial
cells. A primary and fundamental problem which still
exists in the field is a lack in the understanding of how
epithelial CFTR is processed, what the exact nature of
CFTR’s stoichiometry is, and what epithelial accessory
proteins interact with epithelial CFTR in the ER, in the
Golgi and other organelles, and at the plasma mem-
brane. The discovery and development of CF corrector
drugs such as Vertex’s VX-809 being examined in CF
clinical trials currently is also influenced by this biology
and the concept of a ΔF-CFTR dominant negative inhib-
ition of WT-CFTR when expressed together within an
epithelial cell [55,56]. An uncorrected ΔF-CFTR could
conceivably still inhibit a corrected ΔF-CFTR in a simi-
lar dominant negative manner.
There was a premise within the CF research commu-
nity that only 10% of cells along the CF airway or a 10%
correction of ΔF-CFTR within a given CF cell would be
sufficient for a successful therapy. A 10-20% level of cor-
rection was achieved with VX-809 in a recent published
study [55]. However, VX-809 itself does not appear po-
tent or effective enough as a single drug in recent clin-
ical trials; it was disappointing by itself in a combination
trial with the CFTR potentiator drug, VX-770 (ivacaftor,
Kalydeco™) in ΔF-CFTR homozygous patients. It is now
felt that a 50% level of correction is a better benchmark
that is equivalent to 27°C reduced temperature co-
rrection in a biochemical correction assay. This also
approaches the CF heterozygous condition where a car-
rier would have 50% of the functional CFTR than a nor-
mal or WT individual. This level may need to be the
new benchmark for a ΔF-CFTR correction therapy.
While many members in the CF field have been resistant
to the concept that the CF heterozygote may harbor dys-
function since CF heterozygotes do not display a fully
developed CF disease phenotype, correction of a ΔF-
CFTR bearing homozygote to a ΔF-CFTR bearing het-
erozygote would control CF disease. Our work also sug-
gests that more research should be done addressing both
the CF patient and the heterozygotic CF carrier in con-
trast to the normal or non-CF WT controls. Onesuggestion from these studies is that WT mice, CF het-
erozygous mice, and CF homozygous mice, especially
within ΔF-CFTR mouse models, should be studied as
three separate experimental groups in the future. In par-
ticular, these three experimental groups may be inform-
ative to the study of CFTR biology and its influence on
other epithelial cell functions.
Conclusions
Taken together, ΔF-CFTR inhibition of WT-CFTR dur-
ing protein processing in the ER of native CF human
bronchial epithelial cells explains CF-like disease symp-
toms but not fully developed CF disease in CF heterozy-
gous carriers, the majority of whom are WT/ΔF carriers
in the overall population. Attainment of CF heterozygote
level of function with CF corrector drugs and other
strategies would also serve as a critical benchmark for
CF therapy in the near future. Finally, we propose that
both ER-resident chaperones and PDZ-binding proteins
likely play critical roles in CFTR-driven multimeric, oli-
gomeric and/or macromolecular complex formation that
provide a suitable environment for ΔF-CFTR dominant
negative inhibition of WT-CFTR processing and, thus,
trafficking and function.
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